<?xml version="1.0" encoding="UTF-8"?>
<p id="p0045">The total of 10 cell lines (9 cancer cells a normal AML12 hepatocyte) used in this study. Previous reports provided their origins and their characteristics; both drug-sensitive CCRF-CEM leukemia cells and its multidrug-resistant P-glycoprotein-overexpressing subline CEM/ADR5000 cells [
 <xref rid="bib15" ref-type="bibr">15</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref>, 
 <xref rid="bib17" ref-type="bibr">17</xref>], HCT116 
 <italic>p53</italic>
 <sup>
  <italic>+/+</italic>
 </sup> colon cancer cells and its knockout clone HCT116 
 <italic>p53</italic>
 <sup>
  <italic>−/−</italic>
 </sup>, U87.MG glioblastoma cells and its EGFR-transfected U87.MGΔ
 <italic>EGFR</italic> subline, MDA-MB-231-pcDNA3 breast cancer cells and 
 <italic>BCRP</italic>-transfected, multidrug-resistant MDA-MB-231-
 <italic>BCRP</italic> clone 23 cells [
 <xref rid="bib18" ref-type="bibr">18</xref>] were investigated. Besides HepG2 liver cancer cells [
 <xref rid="bib19" ref-type="bibr">19</xref>], and normal AML12 hepatocytes were also used; AML12 hepatocytes were used to compare with HepG2 cells [
 <xref rid="bib19" ref-type="bibr">19</xref>].
</p>
